Implantable devices for the treatment of Congestive Heart Failure (CHF)
EBR Systems, Inc., founded in 2003 and headquartered in Sunnyvale, CA, is developing the WiCS® Wireless Cardiac Stimulation technology to eliminate cardiac pacing leads, historically a major source of complications and reliability issues. The startup was spun out of research by founder Debra Echt, a former professor of medicine and a cardiologist at Vanderbilt University. Continue reading
From Patent Application Publication: US 2011/0137370 A1
Enopace Biomedical Ltd. was founded in 2008 by Yossi Gross in Caesarea, Israel.
Very scant details are available besides that it is developing a neuromodulation system to treat patients with congestive heart failure. According to the company, its technology consists of a minimally invasive, implantable neurostimulation device that increases cardiac efficiency by reducing left ventricular workload.
From Enopace’s patent applications, it seems that Enopace’s device consists of a stimulation unit that is placed within the aorta close to the heart, and which is driven wirelessly from a coil that is placed within a vein closeby to the artery. The transmitting coil is in turn driven from an implanted control unit that is implanted subcutaneously. Continue reading
Image Credit: Respicardia
Respicardia, Inc. (formerly Cardiac Concepts, Inc.) is a privately held medical device company incorporated in 2006. It is located in Minneapolis, Minnesota, USA. It is developing an implantable system intended to improve the outcomes for Heart Failure patients by developing an implantable stimulation therapy to treat Central Sleep Apnea.
The remedē System is an implantable medical device that is being investigated in a clinical research study for the treatment of Central Sleep Apnea in patients with Heart Failure. It consists of three implantable components:
Photo Credit: PRNewsFoto/Angel Medical Systems
Angel Medical was founded by Dr. Robert E. Fischell and Dr. David R. Fischell. The AngelMed Guardian® system is an implantable cardiac device, designed to detect rapid ST segment shifts that may signify major cardiac events, such as coronary artery occlusions caused by life-threatening vulnerable plaque ruptures. Once an ST shift is detected, the system is designed to alert patients to seek medical care by delivering a series of vibratory, auditory, and visual warnings. The AngelMed Guardian system is intended to address the challenge of patients not recognizing nor responding quickly to heart attacks. Continue reading
Yossi Gross (born February 5, 1947) is an Israeli medical device innovator and entrepreneur. His medical-device companies are incubated through Rainbow Medical.
Currently, the following companies led by Yossi Gross are focusing on active implantable medical devices:
Dr. Shlomo Ben-Haim has held faculty appointments as a Professor of Medicine, Physiology and Biophysics, at both Harvard University and the Technion – Israel Institute of Technology. His formal education is in the fields of nuclear physics, mathematics, biomedical engineering, philosophy, and medicine. Dr. Ben-Haim has published his research in over 100 scientific papers, in peer-reviewed journals. He holds over 180 patents and patent applications.
Currently, two companies led by Dr. Ben-Haim are focusing on active implantable medical devices:
Morgan Technical Ceramics (MTC) announced that its Bedford, Ohio site manufactures the piezoelectric ceramic materials used in EBR Systems, Inc.’s innovative new WiCS® Wireless Cardiac Stimulation System. The PZT (lead zirconate titanate) material made by MTC is critical to the efficiency of the WiCS system, which is powered by a battery with a 10-year lifespan.
The WiCS technology, which recently began clinical trials, is the first truly wireless pacing device. It was developed to eliminate cardiac pacing leads, historically a major source of complications and reliability issues. Continue reading
Impulse Dynamics’ OPTIMIZER™ III Implantable Pulse Generator delivers Cardiac Contractility Modulation (CCM), non-excitatory electrical signals during the myocardial absolute refractory period in synchrony with locally sensed electrical activity. CCM signals are intended to treat patients with symptomatic heart failure despite appropriate medical treatment. Continue reading